Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Jan

Today In Oncology

New Study Shows Increased Cancer Mortality Among Patients With Type 2 Diabetes in England

Trends in Use of Next-Generation Sequencing in U.S. Patients According to Genetic Ancestry

Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation

Addition of Pazopanib to Concurrent Radiotherapy and Paclitaxel in Anaplastic Thyroid Cancer

New Analysis Sheds Light on Potential Link Between Ovulation and Ovarian Cancer

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos